New hope for advanced liver cancer: drug duo tested in phase 2 trial

NCT ID NCT05257590

Recruiting now Disease control Sponsor: TaiRx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CVM-1118 combined with an immunotherapy drug (nivolumab) in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will take part to see if the combination shrinks tumors and how long any benefit lasts. The goal is to control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatocellular carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Kaohsiung Chang Gung Memorial Hospital
RECRUITING

Kaohsiung City, Taiwan
Keelung Chang Gung Memorial Hospital
RECRUITING

Keelung, Taiwan
National Cheng Kung University Hospital
RECRUITING

Tainan, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, 100, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, 112, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.